PDF file: EURASNET Annual Report 2008

More documents

Recommendations

Info

total costs * 18.891,12 52778.60 41.219,0110A Total Person-month 32.5 32.5 32,5Personnel costs 26.024,09 26.492,74 27.268,92consumables 22.873,19 30.056,40 16.205,06training 0equipment 0 722,80 722,80travel 518,00 1.209,66 6.041,38overhead 23.207,66 21.678,79adjustment 438,44 -3.472,69total costs * 49.853,72 81.689,26 68.444,2610B Total Person-month 23 23 23Personnel costs 50.643,11 60.305,15 66.043,25consumables 0 0training 0 0equipment 0 0travel 0 0 1.960,57overhead 44.363,36 52.827,31 52.504,38adjustment 0 0 -3.472,70total costs * 95.006,47 113.132,46 117.035,5011 Total Person-month 14.5 37 32.2Personnel costs 0 30.941,24 33.054,83consumables 32.563,81 2.134,49 0training 0 0 0equipment 0 0 0travel 0 0 0overhead 6.512,76 6.615,15 6.610,97other (the rest) 0 0 0total costs * 39.076,57 39.690,88 39.665,8012A Total Person-month 57 17 8.05Personnel costs 66.186,40 51.695,15 31.750,49consumables 13.398,72 8.507,08 2.889,45training 0 0equipment 0 0travel 339,00 5.855,09 1.734,21overhead 15.984,82 13.211,46 7.274,83other (the rest)total costs * 95.908,22 79.268,78 43.648,9812B Total Person-month 21 29,14 15,75Personnel costs 95 991,14 125.391,66 80.304,77consumables 0 5.631,99training 0 0equipment 0 0travel 330,00 2,80overhead 19264,28 26.205,29 16.060,95other (the rest) 0total costs * 115.585,42 157.231,74 96.365,7212C Total Person-month 21.34 19,49 16Personnel costs 93.524,62 92.996,28 105.860,57consumables 0 5.786,30 10.167,87training 0 0equipment 0 0travel 0 5.220,09 2.158,63overhead 18.704,92 20.800,54 23.637,42other (the rest) 0total costs * 112.229,54 124.803,21 141.824,4912D Total Person-month 6 25,67 18,72Personnel costs 22.831,01 100.066,22 88.446,38consumables 0 190,22 385,26123
training 0 0equipment 0 0travel 0 233,05 1.167,32overhead 4.566,20 20.097,89 17.999,78other (the rest) 0total costs * 27.397,21 120.587,38 107.998,7413 Total Person-month 74 74 42.5Personnel costs 0 0consumables 40.924.20 8480 52.364training 0 0equipment 0 0travel 1.480.00overhead 6.505.20 10.472,80other (the rest) 2.302.20total costs * 51.211,60 8480 62.836,8014 Total Person-month 18.2 27,9 30.1Personnel costs 17.092,33 19.061,94 58.714,84consumables 12.171,03 30.172,19 32,828.96training 0 0,00equipment 0 4.647,49 5.529,29travel 1.302.24 2.146,40 2.279,75overhead 6.113,12 10.060,06 15.512,60other (the rest) 0total costs * 36.678,73 66.088,08 114,865.4615 Total Person-month 45 45 40.2Personnel costs 0.00 8704.67 146,14consumables 42,134.39 13810.25 17.919,67training 0.00equipment 0.00travel 5,489.37 5884.23 7.635,29overhead 0.00 5895.81 155,82other (the rest) 1,240.98 1079.89 2.020,78total costs * 48.864,74 35,374.85 27.877,7016 Total Person-month 34.5 28 47,5Personnel costs 4.195,00 36.752,00 34.473,76consumables 34.390,54 12.480,61 0training 0 0 0equipment 541,02 0 0travel 1.963,58 10.310,79 5.152,99overhead 8.383,39 11.908,68 7.925,35other (the rest) 826,83 0total costs * 50.300,36 71.452,08 47.552,1017 Total Person-month 37.5 37.5 41.1Personnel costs 8,481.63 43389.22 15.167,70consumables 5.896,07 5539.92 6.041,33trainingequipment 38.319,97 1.255,57travel 711,34overhead 10.539,53 9785.84 4.635,19other (the rest)total costs * 63.237,20 58714.98 27.811,1318 Total Person-month 14 14 14.2Personnel costs 3.210,51 0 0consumables 24.079,98 21.872,52 11.867,03training 703,75 0 0equipment 0 0 0travel 7.976,61 8.157,13 2.916,13overhead 7.203,88 6.005,93 14.264,52124
Page 3 and 4:
TABLE OF CONTENTSA. PERIODIC ACTIVI
Page 5 and 6:
1 PUBLISHABLE EXECUTIVE SUMMARY EUR
Page 7 and 8:
Dr. Davide Gabellini(28) Swiss Inst
Page 9 and 10:
WP7 Molecular characterization of s
Page 11 and 12:
To identify protein-protein interac
Page 13 and 14:
expressed in a particular tissue. T
Page 15 and 16:
Duchenne muscular dystrophy (DMD).
Page 17 and 18:
WP21 Reachout to the broader RNA co
Page 19 and 20:
4.1 TABLE OF MILESTONES JPA MONTH 2
Page 21 and 22:
Numerous plasmids, constructs, extr
Page 23 and 24:
collaboration between EURASNET and
Page 25 and 26:
5.1 WORK PACKAGE REPORTSWork Packag
Page 27 and 28:
• Ongoing regular addition of new
Page 29 and 30:
Work Package 4 The Alternative Spli
Page 31 and 32:
Work Package 6 In silico approaches
Page 33 and 34:
alternative splicing.162 Compare sp
Page 35 and 36:
33 Agreement on pre-mRNA substrates
Page 37 and 38:
its numerous binding sites on both
Page 39 and 40:
Work Package 8 Genome-wide Analyses
Page 41 and 42:
173 Further development of data ana
Page 43 and 44:
Problems and explanations for delay
Page 45 and 46:
eveal that there is a dramatic chan
Page 47 and 48:
Work Package 10 Post-translational
Page 49 and 50:
mutational analysis that led to the
Page 51 and 52:
Isolation of an active step I splic
Page 53 and 54:
FBP11 and 21 with these sequences.
Page 55 and 56:
Similarly to what observed for SF2/
Page 57 and 58:
prp45-113 mutant, which is compatib
Page 59 and 60:
cell lines. In contrast in the pres
Page 61 and 62:
genes with roles in the development
Page 63 and 64:
Structural analyses of several RRMs
Page 65:
Work Package 17 Staff Exchange and
Page 69 and 70:
Barralle's lab, Krämer is acting a
Page 71 and 72:
alternative splicing) and higher ed
Page 73 and 74: Student Symposium “Decision Makin
Page 75 and 76: variation and suitability for use w
Page 77 and 78: Following feedback from members we
Page 79 and 80: Invited seminars: In addition to me
Page 81 and 82: Publications 2008Author Title Publi
Page 83 and 84: Author Title Publication EURASNET P
Page 93 and 94: Minutes of the General Assembly dec
Page 96 and 97: 241 Evaluate available careerdevelo
Page 98 and 99: 156 The EURASNET memberStamm publis
Page 100 and 101: y coarse-grained foldingsimulation.
Page 102 and 103: overexpressor and mutant lines(mont
Page 104 and 105: machinery with particularrespect to
Page 106 and 107: alternative splicing, using theEDI
Page 108 and 109: contemporary findings withinthe EUR
Page 118 and 119: Licht K, Medenbach J, Lührmann R,K
Page 122 and 123: 9 TABULAR OVERVIEW OF MAJOR COST IT
Page 126 and 127: other (the rest) 48,57 0 56.539,43t
Page 128 and 129: travel 6.964,91overhead 3.081,07oth
Page 130 and 131: Participant 1A Type of expenditure
Page 132 and 133: Participant 1B - Karla Neugebauera)
Page 134 and 135: Participant 2 - Juan Valcarcela) Wo
Page 136 and 137: Participant 3 - Stefan Stamma) Work
Page 138 and 139: Participant 4 - Göran Akusjärvia)
Page 140 and 141: Participant 5A/B - Peer Bork/Rolf A
Page 142 and 143: Major cost items• ResearchPersonn
Page 144 and 145: Participant 7 - Francisco Barallea)
Page 146 and 147: Francisco Baralle gave a talk to a
Page 148 and 149: alternative splicing on human disea
Page 150 and 151: J. Beggs has had frequent contact w
Page 156 and 157: Participant 12A - Jamal Tazia) Work
Page 158 and 159: Participant 12B - Bertrand Séraphi
Page 160 and 161: Participant 12C - Christiane Branla
Page 162 and 163: Participant 12D - Edouard Bertranda
Page 164 and 165: Participant 13 - Daniel Schümperli
Page 166 and 167: Participant 14 - John W. S. Browna)
Page 168 and 169: Participant 15 - Javier F. Cáceres
Page 170 and 171: • ResearchPersonnelName WP Person
Page 172 and 173: MiscellaneousOligonucleotidesUse of
Page 174 and 175:
Major cost items• ResearchConsuma
Page 176 and 177:
Major cost items• ResearchPersonn
Page 178 and 179:
Participant 21 - Angela Krämera) W
Page 180 and 181:
Participant 22 - Angus Lamonda) Wor
Page 182 and 183:
Participant 23 - Chris Smitha) Work
Page 184 and 185:
ChemicalsEnzymesLaboratory supplies
Page 186 and 187:
Participant 26 - Didier Auboeufa) W
Page 188 and 189:
tool for the molecular analysis of
Page 190 and 191:
Participant 29 - Frédéric Allaina
Page 192 and 193:
protein and instead possesses the d
Page 194 and 195:
+ overhead 4.730= total eligible co
Page 196 and 197:
Claudia Tamaro (PhD) has begun work
Page 198 and 199:
ETHZIIMCBUPFSOTON-HGDTOTALJoint Pro
Page 200 and 201:
Direct eligible costs 53.240,48 0,0
Page 202 and 203:
Direct eligible costs 18.720,07 0,0
Page 204 and 205:
13 REPORT ON THE DISTRIBUTION OF TH
Page 206 and 207:
Report on the Distribution of the C
Page 208 and 209:
For most work packages here follows
Page 210 and 211:
pathways (eg, Reactome ).While PAND
Page 212 and 213:
The possible dependence of the effe
Page 214 and 215:
In some treatments or mutants, simi
Page 216 and 217:
Work Package 12: Mis-splicing and D
Page 218 and 219:
acid. Furthermore, using antibodies
Page 220 and 221:
At the 2007 annual meeting in Ile d
Page 222 and 223:
Partner 13 has extensively studied
Page 224 and 225:
inhibitors/modulators of RNA splici
Page 226 and 227:
18 MONTH JPA: WORKPACKAGE TIMECOURS
Page 228 and 229:
15.3 GRAPHICAL PRESENTATION OF WORK
Page 230 and 231:
15.4 TABLE OF MILESTONES (MONTH 37-
Page 232 and 233:
156 The EURASNET memberStamm publis
Page 234 and 235:
194 Bertrand will analyze indetail
Page 236 and 237:
216 Aubeouf and Neugebauer willcoll
Page 238 and 239:
238 Establishing joint PhDcommittee
Page 240 and 241:
283 A unified browser for allknown
Page 242 and 243:
296 Group 12a (Branlant) willuse th
Page 244 and 245:
315 Lamond will use a FLIM-FRET bas
Page 246 and 247:
329 GROUP 7 (F. BARALLE)will contin
Page 248 and 249:
333 GROUP 27 (GABELLINI)will:1) foc
Page 250 and 251:
345 Schümperli’s group isplannin
Page 252 and 253:
366 Quarterly network e-mail atmont
Page 254 and 255:
2. Sharing Resources, Technology an
Page 256 and 257:
5. Ensuring DurabilityWorkpackage d
Page 258 and 259:
7. Molecular Characterization of Sp
Page 260 and 261:
8. Genome-wide Analyses of Splicing
Page 262 and 263:
9. Complexity of Spliceosomal Prote
Page 264 and 265:
202 Srebrow will investigate the ro
Page 266 and 267:
12. Mis-splicing and DiseaseWorkpac
Page 268 and 269:
13. Co-transcriptional Mechanisms o
Page 270 and 271:
14. Chemical Biology and Therapeuti
Page 272 and 273:
15. Development of Enabling Technol
Page 274 and 275:
269 IFMs in 20091. “Alternative a
Page 276 and 277:
18. Career DevelopmentWorkpackage d
Page 278 and 279:
20. SMEs and Technology TransferWor
Page 280 and 281:
21. Reachout to the Broader RNA Com
Page 282 and 283:
15.7 WORK PACKAGE LIST (MONTHS 37-5
Page 284 and 285:
ETHZIIMCBUPFSOTON-HGDTOTALJoint Pro
Page 286 and 287:
AMU 5 29 8 42UAAR 5 145 16 1665 29
Page 288 and 289:
Joint Programme of Activities RESEA
Page 290 and 291:
60 month period 18 month periodRequ
Page 292 and 293:
Integration1. Young Investigator Pr
Page 294 and 295:
UCAM-DBIOC 2350,000x1/3 € 50,000x
Page 296:
the management team. Audit costs ar
show all

PDF file: EURASNET Annual Report 2008

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?